Qurient Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2008-07-02
- Employees
- 32
- Market Cap
- -
- Website
- http://www.qurient.com
Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
- Conditions
- Esophageal CancerGastric CancerHepatocellular CancerCervical Cancer
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05438420
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
🇰🇷CHA Bundang Medical Center, Seongnam-si, Korea, Republic of
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
- Conditions
- Metastatic CancerAdvanced Cancer
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT05394103
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients
- Conditions
- COVID-19 Virus Infection
- Interventions
- Drug: COVID-19 Standard of care
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04847583
- Locations
- 🇿🇦
Chris Hani Baragwanath Academic Hospital, Soweto, Gauteng, South Africa
🇿🇦KwaPhila Health Solutions, Durban, Kwa-Zula Natal, South Africa
🇿🇦TASK Eden, George, Western Cape, South Africa
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor
- Conditions
- Solid TumorAdvanced CancerMetastatic Cancer
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT04648254
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: VehicleDrug: Q301 Cream
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 258
- Registration Number
- NCT03571620
- Locations
- 🇺🇸
Wake Forest School of Medicine Department of Dermatology, Winston-Salem, North Carolina, United States
- Prev
- 1
- 2
- Next